Unicycive Therapeutics

Unicycive Therapeutics company information, Employees & Contact Information

Unicycive Therapeutics invent and develop medications that help kidney patients feel their best and enjoy the best possible quality of life.

Company Details

Employees
24
Founded
-
Address
5150 El Camino Real Suite A 32, Los Altos,ca 94042,united States
Phone
(650) 384-0642
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Los Altos, CA
Looking for a particular Unicycive Therapeutics employee's phone or email?

Unicycive Therapeutics Questions

News

Unicycive Therapeutics Provides Update from FDA Type A - GlobeNewswire

Unicycive Therapeutics Provides Update from FDA Type A GlobeNewswire

Kidney Disease Biotech Unicycive Therapeutics Sets Two Major Investor Conference Appearances in September - Stock Titan

Kidney Disease Biotech Unicycive Therapeutics Sets Two Major Investor Conference Appearances in September Stock Titan

Unicycive Therapeutics Regains Compliance with Nasdaq Listing Standards Following Share Price Recovery - Quiver Quantitative

Unicycive Therapeutics Regains Compliance with Nasdaq Listing Standards Following Share Price Recovery Quiver Quantitative

Unicycive Sets 1-for-10 Reverse Split: What This Means for 126M Outstanding Shares - Stock Titan

Unicycive Sets 1-for-10 Reverse Split: What This Means for 126M Outstanding Shares Stock Titan

Unicycive Therapeutics to Participate in Upcoming Investor Events in September - GlobeNewswire

Unicycive Therapeutics to Participate in Upcoming Investor Events in September GlobeNewswire

Clinical-Stage Kidney Disease Biotech Unicycive Reveals Latest Therapeutic Progress at Major Healthcare Conference - Stock Titan

Clinical-Stage Kidney Disease Biotech Unicycive Reveals Latest Therapeutic Progress at Major Healthcare Conference Stock Titan

Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update GlobeNewswire

Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease - GlobeNewswire

Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease GlobeNewswire

Unicycive Therapeutics Announces Receipt of Complete - GlobeNewswire

Unicycive Therapeutics Announces Receipt of Complete GlobeNewswire

Unicycive Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire

Unicycive Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire

Unicycive Therapeutics Announces the Publication of - GlobeNewswire

Unicycive Therapeutics Announces the Publication of GlobeNewswire

Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewswire

Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement GlobeNewswire

Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update GlobeNewswire

Unicycive Provides Update on New Drug Application for - GlobeNewswire

Unicycive Provides Update on New Drug Application for GlobeNewswire

Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire

Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update GlobeNewswire

Unicycive Presents New Patient-Level Data Underscoring - GlobeNewswire

Unicycive Presents New Patient-Level Data Underscoring GlobeNewswire

Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders - GlobeNewswire

Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders GlobeNewswire

Unicycive Therapeutics Announces the Publication of Patient - GlobeNewswire

Unicycive Therapeutics Announces the Publication of Patient GlobeNewswire

Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire

Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update GlobeNewswire

Unicycive Therapeutics Announces U.S. FDA Acceptance of the - GlobeNewswire

Unicycive Therapeutics Announces U.S. FDA Acceptance of the GlobeNewswire

Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024 - Yahoo Finance

Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024 Yahoo Finance

Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024 - Yahoo Finance

Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024 Yahoo Finance

Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers - GlobeNewswire

Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers GlobeNewswire

Unicycive Announces $50 Million Private Placement - GlobeNewswire

Unicycive Announces $50 Million Private Placement GlobeNewswire

Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024 - Stock Titan

Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024 Stock Titan

Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD - Yahoo Finance

Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD Yahoo Finance

Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb - GlobeNewswire

Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb GlobeNewswire

Unicycive Therapeutics Announces Pricing of Initial Public Offering - PR Newswire

Unicycive Therapeutics Announces Pricing of Initial Public Offering PR Newswire

Unicycive Therapeutics Announces Second Quarter 2021 Financial Results - PR Newswire

Unicycive Therapeutics Announces Second Quarter 2021 Financial Results PR Newswire

60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R) - Stock Titan

60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R) Stock Titan

Top Unicycive Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant